LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The programmed cell death 1 (PD-1) pathway is a key regulator of immune responses, particularly in the tumor microenvironment.
• PD-1 pathway inhibitors have revolutionized cancer treatment, prompting research into alternative immune checkpoints.
• Lymphocyte activation gene 3 (LAG3) is an emerging inhibitory immune checkpoint molecule with potential therapeutic applications.

Purpose of the Study:

• To review the biological role of Lymphocyte Activation Gene 3 (LAG3).
• To analyze LAG3 expression in breast cancer.
• To summarize current clinical trials involving LAG3-targeting immunotherapies.

Main Methods:

• This is a narrative review.
• Literature search on the biological role of LAG3 in infection, autoimmune disease, and cancer.
• Analysis of current data on LAG3 expression in breast cancer.
• Summary of ongoing clinical trials for LAG3-based therapies.

Main Results:

• LAG3 plays a role in regulating immune responses across various conditions, including cancer.
• LAG3 expression is observed in breast cancer, suggesting its relevance in this malignancy.
• Multiple clinical trials are investigating LAG3-targeting agents, including soluble LAG3 immunoglobulin and antagonists.

Conclusions:

• LAG3 represents a promising target for novel cancer immunotherapies.
• Combinatorial approaches involving LAG3 blockade may enhance anti-tumor immunity.
• Further research and clinical evaluation of LAG3-based treatments are warranted.